Bone mineral density and bone turnover in hyperprolactinaemia of various origins.
BACKGROUND
Osteopenia and osteoporosis because of hyperprolactinaemia caused by prolactinoma may be followed by an increased risk of fracture. There are no data on the bone effects of functional hyperprolactinaemia. The aim was to assess the influence of hyperprolactinaemia of various origins on bone turnover and density in different skeletal sites.


METHODS
The study was carried out in 75 women (aged 30.53 +/- 7.8): Group I--32 women with prolactinoma and Group II--43 women with functional hyperprolactinaemia. Both groups of patients were subdivided into those with hypogonadism and those with normal gonadal function. The control group consisted of 29 healthy women aged (33.59 +/- 4.7). In all subjects PRL and bone turnover markers (BAP, OC, ICTP) were studied. BMD measurements (lumbar spine, forearm, proximal femur and total body) were carried out using DXA.


RESULTS
Higher PRL concentrations were observed in patients than in controls. The values of bone turnover markers (BAP, ICTP) were shown to be higher in patient groups and subgroups than in controls. In patients with prolactinoma lumbar spine BMD was lower than in patients with functional hyperprolactinaemia and controls. Total body BMD was also lower, albeit to a lesser extent.


CONCLUSIONS
Hyperprolactinaemia caused by prolactinoma in women influences bone metabolism unfavourably, more by the impact on the activity of bone turnover markers than on BMD. This provides an opportunity for earlier assessment of bone metabolism disturbances before the BMD changes can be observed. Functional hyperprolactinaemia does not determine such a harmful effect on bone metabolism as hyperprolactinemia due to prolactinoma.
Zadrozna-Sliwka
Beata
B
Department of Endocrinology, Diabetology and Isotope Therapy, Wrocław Medical University, Wrocław.
Bolanowski
Marek
M
Kałuzny
Marcin
M
Syrycka
Joanna
J
D000328:Adult; D000469:Alkaline Phosphatase / Q000097:blood; D015415:Biomarkers / Q000097:blood; D015519:Bone Density; D016723:Bone Remodeling; D024042:Collagen Type I; D005260:Female; D006801:Humans; D006966:Hyperprolactinemia / Q000097:blood / Q000150:complications* / Q000503:physiopathology*; D008159:Lumbar Vertebrae / Q000503:physiopathology; D008875:Middle Aged; D015675:Osteocalcin / Q000097:blood; D010024:Osteoporosis / Q000175:diagnosis / Q000209:etiology* / Q000503:physiopathology; D010446:Peptide Fragments / Q000097:blood; D010455:Peptides; D010911:Pituitary Neoplasms / Q000097:blood / Q000150:complications; D011347:Procollagen / Q000097:blood; D011388:Prolactin / Q000097:blood*; D015175:Prolactinoma / Q000150:complications* / Q000503:physiopathology; D012016:Reference Values
D015415:Biomarkers; D024042:Collagen Type I; D010446:Peptide Fragments; D010455:Peptides; D011347:Procollagen; C052929:collagen type I trimeric cross-linked peptide; D015675:Osteocalcin; D011388:Prolactin; D000469:Alkaline Phosphatase